🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "huge turning point" in the effort against drug-resistant strains of the infection, according to health experts.

A Worldwide Challenge

The sexually transmitted infection are increasing globally, with data suggesting more than 82 million infections each year. Notably increased rates are observed in the African continent and countries within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. In England, cases have reached a historical peak, while infection numbers across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an important and timely advancement in the context of growing infection rates, increasing antimicrobial resistance and the highly restricted treatment choices currently available.”

Health officials are particularly alarmed about the increase in drug-resistant strains. The World Health Organization has listed it as a "critical concern". A tracking program showed that the effectiveness of primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Drugs Secure Approval

One new antibiotic, also known as a brand name, was authorized by the US FDA in December for combating gonorrhoea. This STI can lead to major issues, including infertility. Scientists anticipate that targeted use of this new drug will help slow the development of resistance.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, also received approval in concurrent days. This drug, which is additionally indicated for UTIs, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Unique Development Model

This new treatment was the result of a innovative non-profit model for antibiotic development. The charitable organization GARDP worked alongside the pharmaceutical company Innoviva to see it through.

“This approval represents a significant shift in the treatment of multidrug-resistant gonorrhoea, which previously has been outpacing antibiotic development.”

Clinical Trial Results and Global Access

Based on findings detailed in a prominent scientific publication, the new drug cured over nine in ten of cases of the STI. This places it at an similar efficacy with the typical regimen, which involves a dual-drug approach. The study included nearly 1,000 volunteers from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its collaboration, the non-profit has the rights to register and commercialise the drug in a wide range of developing nations.

Medical professionals directly involved have shared hope. Having a easy-to-administer therapy like this is hailed as a "critical tool" for gonorrhoea control. This is considered essential to alleviate the strain of the disease for people and to prevent the spread of extremely resistant gonorrhoea around the world.